Research programme: melanoma vaccine - AlphaVax/Memorial Sloan-Kettering Cancer Center

Drug Profile

Research programme: melanoma vaccine - AlphaVax/Memorial Sloan-Kettering Cancer Center

Alternative Names: Alphavirus replicon vaccine expressing tyrosinase-related protein 2 antigen- AlphaVax; TRP2 melanoma vaccine - AlphaVax

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma

Most Recent Events

  • 02 Mar 2017 Preclinical development is ongoing for Malignant melanoma (Prevention) in USA (AlphaVax pipeline, March 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma(Prevention) in USA (Parenteral)
  • 13 May 2009 Preclinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top